HPV分型联合TP53突变分析鉴别头颈鳞癌第二原发肺肿瘤与肺转移
本研究对32例头颈鳞状细胞癌(HNSCC)合并肺肿瘤患者,采用HPV分型及TP53全部编码外显子的靶向二代测序分析肺肿瘤起源。29例可明确判定为HNSCC转移或第二原发肿瘤,其中16例仅凭临床和形态学数据被误诊。提示HPV分型联合TP53突变分析有助于鉴别诊断并指导治疗选择。
要点
- HPV分型联合TP53全编码外显子测序可鉴别HNSCC肺转移与第二原发肺鳞癌。
- 32例中29例可明确肺肿瘤起源,16例仅凭临床和形态学被误诊。
- 准确鉴别有助于确保HNSCC合并肺鳞癌患者接受最合适的治疗。
核心结论
- HPV分型联合TP53全部编码外显子突变分析是鉴别HNSCC合并肺鳞癌起源的有价值诊断工具。
研究设计与样本
- 对32例HNSCC患者的肺肿瘤进行HPV分型和TP53全部编码外显子的靶向二代测序分析。
主要发现
- 29例肺肿瘤被明确判定为HNSCC转移或第二原发肿瘤。
- 16例仅凭临床和形态学数据被误诊。
临床怎么用
- 对HNSCC合并肺鳞癌患者,可采用HPV分型联合TP53全编码外显子测序辅助鉴别肺肿瘤起源。
- 准确鉴别肺肿瘤起源有助于为患者选择最合适的治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In head and neck squamous cell carcinoma (HNSCC), the occurrence of concurrent lung malignancies poses a significant diagnostic challenge because metastatic HNSCC is difficult to discern from second primary lung squamous cell carcinoma (SCC). However, this differentiation is crucial because the recommended treatments for metastatic HNSCC and second primary lung SCC differ profoundly. METHODS: We analyzed the origin of lung tumors in 32 patients with HNSCC using human papillomavirus (HPV) typing and targeted next generation sequencing of all coding exons of tumor protein 53 (TP53). RESULTS: Lung tumors were clearly identified as HNSCC metastases or second primary tumors in 29 patients, thus revealing that 16 patients had received incorrect diagnoses based on clinical and morphological data alone. CONCLUSION: The HPV typing and mutation analysis of all TP53 coding exons is a valuable diagnostic tool in patients with HNSCC and concurrent lung SCC, which can help to ensure that patients receive the most suitable treatment.
引用
- Daher T, Tur MK, Brobeil A, et al. Combined human papillomavirus typing and TP53 mutation analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. Head Neck. 2018. PMID: 29522268. doi:10.1002/hed.25041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。